On August 24, 2016 TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, reported its participation in four upcoming investor conferences (Press release, TESARO, AUG 24, 2016, View Source [SID:1234514709]). The four conferences are:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Wells Fargo Global Healthcare Conference at the Westin Boston Waterfront in Boston on Wednesday, September 7. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will participate in an analyst-led moderated Q&A from 3:30 to 4:00 PM ET and in meetings with investors.

The 11th Annual Citi Biotech Day at the Mandarin Oriental Hotel in Boston on Thursday, September 8, 2016. Lonnie Moulder will participate in a panel titled "Developing Cancer Therapeutics in 2016" at 8:00 AM ET. Also, Lonnie Moulder and Mary Lynne Hedley, Ph.D. will host meetings with investors.

The Baird 2016 Healthcare Conference at the New York Palace Hotel in New York City on Thursday, September 8. Tim Pearson, EVP and CFO of TESARO, is scheduled to participate in an analyst-led fireside chat from 12:15 to 12:45 PM ET, and in meetings with investors.

The Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology at the Lotte New York Palace in New York City on September 29, 2016. Lonnie Moulder and Jeff Hanke, Ph.D., EVP and Chief Scientific Officer of TESARO, will participate in an analyst-led fireside chat from 1:00 to 1:30 PM ET, and in meetings with investors.